BCI and AI. Exploring practical developments and perspectives on artificial intelligence. https://kimkj.com/podcast/bci-ai-en en Kyungjin Kim Kyungjin Kimkimkj008@gmail.com episodic false A compilation for 31 October 2026 built from material provided by attorney Kyungjin Kim, focused on introducing and explaining the original sources. 1. Precision Neuroscience signs a two-year research MoU with Cleveland Clinic Abu Dhabi, its first clinical research site outside the U.S. 2. The Layer 7 cortical interface: device specifications and current U.S. FDA status 3. ISO/IEC publishes a China-led international standard on brain-computer interface reference architecture Each segment was generated separately as a Brief from a single selected source and then joined in order. The programme introduction appears only in the first segment. Claims, figures and assessments belong to the cited sources, not to attorney Kim. Audio was AI-generated. The closing provider notice at the end is a Korean AI voice line. kimkj-bci-ai-en-20261031 Sat, 31 Oct 2026 19:00:48 +0900 223 false An English Brief compilation based on material provided by attorney Kyungjin Kim. Actual duration: 4 minutes 51 seconds, about five minutes. No silence, slowed playback or unsupported material was added to fill time. 1. Xinhua reported Shanghai StairsMed WRS-01 company figures on 28 October 2026: 256 channels, 42 cumulative implant cases, registered-study recruitment, aggregate implant days/use hours, cursor latency under 0.05 seconds and peak ITR 390 bits/minute. 2. A Frontiers in Neuroscience review: three anatomical approaches, fragmented long-term human data and a proposed lifecycle evaluation framework. This is an academic proposal, not a mandatory regulatory standard. 3. Professor Lim Changhwan at the Seoul Insights session, as reported by Seoul Shinmun: AI as a companion tool, BCI as a next connection, overseas Neuralink/WIMAGINE examples and functional-restoration vision. The foreign cases are article examples, not new clinical data produced by the speaker. Company-reported use metrics are not recast as physiological tolerance, independently proven safety, marketing approval or completed clinical-trial outcomes. An unsafe generated take that made that inference was rejected and preserved as history. Source-specific explanatory transitions are kept; unsupported fear hooks and repeated show introductions were removed. Seoul Shinmun original article: https://www.seoul.co.kr/news/plan/forum/forum-future/2026/10/28/20261028500409 Actual single-source Briefs, AI-generated and edited. Existing GUID and publication date retained. kimkj-bci-ai-en-20261029-trial Thu, 29 Oct 2026 14:30:11 +0000 291 false